Smith & Nephew (LON:SN) Stock Price Passes Above 200 Day Moving Average - What's Next?

Key Points

• Smith & Nephew's share price has crossed above its 200-day moving average, indicating potential bullish momentum.
• The company's market capitalization stands at £12.94 billion, with a notable P/E ratio of 42.48 reflecting the high market expectations.
• Current financial ratios include a debt-to-equity ratio of 70.22 and a current ratio of 2.51, suggesting significant leverage and solid short-term liquidity.

Smith & Nephew plc (LON:SN - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,068.44 ($14.18) and traded as high as GBX 1,182.61 ($15.70). Smith & Nephew shares last traded at GBX 1,180 ($15.66), with a volume of 1,809,060 shares.

Smith & Nephew Stock Performance

The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The firm has a fifty day moving average price of GBX 1,109.28 and a two-hundred day moving average price of GBX 1,071.12. The stock has a market capitalization of £12.68 billion, a PE ratio of 41.64, a P/E/G ratio of 0.46 and a beta of 0.62.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.